Can the patient continue the vitamin D3 supplement that contains 100 µg of vitamin K2 given his current regimen of carvedilol, lisinopril, empagliflozin, and atorvastatin, and the fact that he is not taking a vitamin‑K antagonist such as warfarin?

Yes, the patient can safely continue the vitamin D3 supplement containing 100 µg of vitamin K2

Since the patient is not taking warfarin or any other vitamin K antagonist (VKA), there is no contraindication to vitamin K2 supplementation with his current medication regimen of carvedilol, lisinopril, empagliflozin, and atorvastatin.

Key Reasoning

No Vitamin K Antagonist = No Interaction Concern

The primary concern with vitamin K supplementation relates specifically to patients taking warfarin or other VKAs, where vitamin K directly antagonizes the anticoagulant effect by promoting synthesis of clotting factors 1, 2. Guidelines explicitly recommend that patients receiving anticoagulant medicines that inhibit vitamin K activity (such as warfarin) should not receive vitamin K supplements 3. However, this patient is not on any anticoagulant therapy, making this concern irrelevant.

Medication-Specific Considerations

Atorvastatin and Vitamin D/K2:

• There is evidence of a bidirectional interaction between atorvastatin and vitamin D: vitamin D supplementation may actually decrease atorvastatin concentrations while paradoxically having synergistic effects on cholesterol reduction 4, 5
• However, this interaction is clinically manageable and does not contraindicate combined use 6
• No significant interactions exist between statins and vitamin K2

Other Medications:

• Carvedilol, lisinopril, and empagliflozin have no documented interactions with vitamin K2 or vitamin D3 7, 8
• These cardiovascular medications are routinely used alongside vitamin supplementation without issue

Potential Benefits in This Population

The combination of vitamin D3 and K2 may actually provide cardiovascular benefits:

• Studies suggest vitamin K2 may help regulate vascular calcification through activation of matrix Gla protein 9, 10
• Combined D3 and K2 supplementation has shown improvements in metabolic parameters including glucose control 11
• The 100 µg dose of K2 is within the range used in clinical trials (typically 45-720 µg daily) 11, 12, 13

Important Caveats

Monitor if anticoagulation is ever initiated: Should the patient require warfarin or another VKA in the future (for atrial fibrillation, mechanical valve, or venous thromboembolism), the vitamin K2 supplement must be discontinued immediately 1, 3, 2. Direct oral anticoagulants (DOACs) do not have this interaction with vitamin K 14, 15.

Statin monitoring: Given the potential interaction between vitamin D and atorvastatin, it would be reasonable to monitor lipid panels to ensure adequate cholesterol control is maintained 4, 5.